New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine
The Lancet Infectious Diseases·
- DOI
- 10.1016/s1473-3099(24)00581-4
- PMID
- 39389073
- PMCID
- —
- OpenAlex
- W4403176009
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The abstract frames rhodesiense human African trypanosomiasis as a neglected tropical disease that is generally fatal if untreated. It states that the updated recommendations may matter for health-care professionals and policy makers.
Structured evidence summary
Research question
The article addresses revised WHO treatment guidance for rhodesiense human African trypanosomiasis, with emphasis on expanded use of fexinidazole and pentamidine.
Study design
This is a review article describing WHO guideline development based on an independent systematic literature review and GRADE methodology.
Population and setting
The guidance concerns people with rhodesiense human African trypanosomiasis. Specific eligibility noted in the abstract includes individuals aged at least 6 years and weighing at least 20 kg for fexinidazole.
Main findings
The abstract reports that fexinidazole is now positioned as first-line treatment for eligible patients and can be used across both disease stages, removing the need for lumbar puncture solely for staging. It also reports that pentamidine is suggested as immediate temporary treatment when preferred medicines are unavailable, while younger or lower-weight children are not eligible for fexinidazole under the stated criteria.
Public-health relevance
The abstract frames rhodesiense human African trypanosomiasis as a neglected tropical disease that is generally fatal if untreated. It states that the updated recommendations may matter for health-care professionals and policy makers.
Important limitations
The abstract explicitly states that evidence was scarce and that all recommendations were conditional with very low certainty. This summary is also limited to the supplied single-article abstract and metadata; the full article would be needed for decision-grade interpretation.
GIDS interpretation
The classifier links make this article discoverable under African trypanosomiasis and treatment, with an additional disease classifier for leishmaniasis. No country classifier is supplied, so geographic indexing cannot be specified from the provided metadata.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 6 auditable classifier relationships to diseases, places, topics, and study design.